1-5 of 5
Srinivasu Poondru
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

Helena A. Yu, Alexander Spira, Leora Horn, Jared Weiss, Howard West, Giuseppe Giaccone, Tracey Evans, Ronan J. Kelly, Bhardwaj Desai, Andrew Krivoshik, Diarmuid Moran, Srinivasu Poondru, Fei Jie, Kouji Aoyama, Anne Keating, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (24): 7467–7473.
https://doi.org/10.1158/1078-0432.CCR-17-1447
Published: 14 December 2017
View article titled, A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations
Open the PDF for A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

Valentine M. Macaulay, Mark R. Middleton, S. Gail Eckhardt, Charles M. Rudin, Rosalyn A. Juergens, Richard Gedrich, Sven Gogov, Sean McCarthy, Srinivasu Poondru, Andrew W. Stephens, Shirish M. Gadgeel
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2897–2907.
https://doi.org/10.1158/1078-0432.CCR-15-2218
Published: 14 June 2016
View article titled, Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Igor Puzanov, Colin R. Lindsay, Laura Goff, Jeff Sosman, Jill Gilbert, Jordan Berlin, Srinivasu Poondru, Ronit Simantov, Rich Gedrich, Andrew Stephens, Emily Chan, T.R. Jeffry Evans
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (4): 701–711.
https://doi.org/10.1158/1078-0432.CCR-14-0303
Published: 16 February 2015
View article titled, A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Robin L. Jones, Edward S. Kim, Pilar Nava-Parada, Salma Alam, Faye M. Johnson, Andrew W. Stephens, Ronit Simantov, Srinivasu Poondru, Rich Gedrich, Scott M. Lippman, Stan B. Kaye, Craig P. Carden
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (4): 693–700.
https://doi.org/10.1158/1078-0432.CCR-14-0265
Published: 16 February 2015
View article titled, Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
Open the PDF for Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Timothy A. Yap, Hendrik-Tobias Arkenau, D. Ross Camidge, Suzanne George, Natalie J. Serkova, Stephen J. Gwyther, Jennifer L. Spratlin, Rohit Lal, James Spicer, Nandita M. Desouza, Martin O. Leach, Jon Chick, Srinivasu Poondru, Ramesh Boinpally, Richard Gedrich, Katie Brock, Andrew Stephens, S. Gail Eckhardt, Stan B. Kaye, George Demetri, Michelle Scurr
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 909–919.
https://doi.org/10.1158/1078-0432.CCR-12-2258
Published: 14 February 2013
View article titled, First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Open the PDF for First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies in another window
Includes: Supplementary data